The team Systasy comprises of smart, innovative and talented group of people working towards our goal – decoding complexities. The team brings together experiences required for developing assays for drug profiling & discovering, decoding biological pathways and developing disease relevant cellular test systems.
Dr. Sven Wichert
Chief Executive Officer
Sven Wichert is one of the founders of Systasy Bioscience and an entrepreneurial life science professional with 8 years of experience in startup development. He is responsible for business development, financials, intellectual property management, human resources (HR), and general administration. Sven ensures that all administrative and business-related processes are developed and implemented according to generally approved best practices.
Sven obtained his PhD degree from the University of Heidelberg in 2009. In his scientific career as a bioinformatician, he gained in-depth experience on the analysis of high-throughput datasets and on the development of the EXTassay technology.
Dr. Michael Wehr
Chief Technology Officer
Michael is one of the founders and a life science professional with over 18 years in assay development, high-throughput approaches, and the creation of human disease models for neuroscience. He supervises the teams in Technology and Bioinformatics that develop, validate, and implement standard operating procedures (SOPs) and quality control (QC) measures for cell-based assays and human cellular disease models. In addition, Michael is responsible for implementation of manufacturing processes and scale-up of stem cell production. Furthermore, he manages business development and sales activities in Asia-Pacific and is active in partnered programs.
Michael obtained his degree in Biology from the University of Heidelberg in 2006 for developing the splitSENSOR technique to monitor regulated protein-protein interactions and dynamic receptor activities in living cells. Prior to Systasy, Michael spent four years at the London Research Institute, UK, to combine the splitSENSOR technology with genome-wide cell-based RNAi screens to identify new players implicated in cellular signaling. Back in Germany in 2011, he promoted the product development of Systasy´s splitSENSOR and EXTassay platform technologies into multiparametric assays for market launch. Further, Michael holds strong neuroscience expertise to foster market-ready manufacturing of stem cell technologies.
Dr Moritz Rossner
Chief Scientific Officer
Moritz Rossner is one of the founders and a seasoned scientific manager with extensive experience in molecular and behavioral neurobiology, molecular barcoding techniques, and human cellular disease models for complex brain disorders. Moritz oversees our teams in R&D and manages collaborations with clinicians from various clinical centers to obtain biofluids and stem cells. Actively engaged in Systasy´s business development from the very beginning, he is one of the driving forces behind the partnering in drug discovery programs.
Moritz Rossner studied molecular biology and received his PhD in neurogenetics in 1997. 1998 he joined Axaron Bioscience AG as a group leader focusing on transcriptomic technologies in drug discovery. In 2003 he moved to the Max Planck Institute for Experimental Medicine in Göttingen, where he and his team laid the foundation for the EXTassay technology. Since 2013 he is appointed as professor to the Department of Psychiatry at the LMU in Munich.
Dr Cäcilie Böttge
Chief Marketing Officer
Cäcilie Böttge is a seasoned life science professional with 20+ years of experience in marketing & sales. Following her passion for bringing innovative technologies to the market, she spent half of her career in life science startups. Cäcilie joined Systasy in 2018 and was promoted to Chief Marketing Officer in 2020. Her primary focus is on strategic marketing and supporting the management team in market-oriented product and business development.
Cäcilie studied molecular biology and received her PhD from the University of Cologne in 1992. During her marketing & sales career she gained in-depth expertise in the fields of molecular multiplexing technologies, pharmacogenetics and in vitro diagnostics. Prior to Systasy she created important foundations for the successful expansion of Nanosphere Inc. to Europe, the Middle East, and Asia. Particularly noteworthy is the product optimization initiated and supported by her, which has led to an outstanding unique selling point. With the accompanying strategic product positioning she created a strong global competitive advantage for Nanosphere.